Sort
82,697 grants matching “vaccine development”
Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk
$978,740Eva Harris · University Of California Berkeley · U01 · FY2022 · AI
Improving the Efficacy of Dendritic Cell Vaccines
$978,697Jacques F Banchereau · Baylor Research Institute · P01 · FY2007 · CA
CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2
$978,683Deborah J Donnell · Fred Hutchinson Cancer Research Center · UM1 · FY2021 · AI
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
$978,679David I Watkins · Mabloc, Llc · R42 · FY2023 · AI
New Technology for High-Resolution Antibody Profiling for SARS-CoV-2
$978,625Mark Lim · Ambergen, Inc · R44 · FY2023 · AI
New Technology for High-Resolution Antibody Profiling for SARS-CoV-2
$978,625Mark Lim · Ambergen, Inc · R44 · FY2022 · AI
PfSPZ Vaccines: Quality Systems, Manufacturing, Regulatory, and Clinical Quality and Data Management Support for Product Commercialization
$978,475Stephen Lev Hoffman · Sanaria, Inc. · SB1 · FY2017 · AI
Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB
$978,349Rhea N Coler · Seattle Children'S Hospital · R01 · FY2025 · AI
Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB
$978,338Rhea N Coler · Seattle Children'S Hospital · R01 · FY2024 · AI
Identification of Gene Polymorphisms Associated with Infectious Diseases
$978,326Cheryl Winkler · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Clinical Trials of Biodefense Vaccines (Dengue)
$978,205Kanta Subbarao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
DEVELOPMENT OF A PRIMATE GENOMIC RESOURCE
$978,086Michael G Katze · University Of Washington · R24 · FY2009 · RR
SBIR Phase II: High-capacity membrane for fast and selective capture of mRNA
$977,854Graham Temples · Purilogics, Llc · R44 · FY2021 · GM
Immunology of aging and immunotherapy of aging-associated diseases
$977,820Bira Arya · National Institute On Aging · ZIA · FY2015 · AG
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector
$977,629David A Williams · Boston Children'S Hospital · U01 · FY2012 · AI
Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.
$977,597Stephen Lev Hoffman · Sanaria, Inc. · SB1 · FY2019 · AI
Tulane National Primate Research Center
$977,475Benjamin Paul Sachs · Tulane University Of Louisiana · P51 · FY2009 · RR
Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral
$977,449Gai Liu · Microbiotix, Inc · R42 · FY2025 · AI
Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites
$977,419Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2021 · AI
Novel vaccine against Norovirus
$977,357Xi Jiang · Cincinnati Childrens Hosp Med Ctr · R01 · FY2011 · AI
Harvard Medical School Vaccine Clinical Trials Unit
$977,281Raphael Dolin · Harvard Medical School · U01 · FY2008 · AI
St. Jude/Memphis IMPAACT Clinical Trials Unit
$977,266Patricia Michele Flynn · St. Jude Children'S Research Hospital · U01 · FY2008 · AI
Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine
$977,255Hannah Frizzell · Orlance, Inc. · R44 · FY2025 · AI
Pre-Clinical HPV16 Antiviral Compound Development
$977,163Christopher Fisher · Nanovir, Llc. · R42 · FY2009 · AI
Basis for Success of Multidrug-Resistant Enterobacteriaceae
$977,026Frank Deleo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI